Athina Ntoumaziou,Mary Risinger,Yasmin Elgammal,Wenying Zhang,Theodosia A Kalfa,Luke R Smart
{"title":"Cryohydrocytosis: When Cold Breaks the Membrane.","authors":"Athina Ntoumaziou,Mary Risinger,Yasmin Elgammal,Wenying Zhang,Theodosia A Kalfa,Luke R Smart","doi":"10.1002/ajh.70274","DOIUrl":"https://doi.org/10.1002/ajh.70274","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"56 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147371018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anna Maria Raiola,Paola Contini,Massimiliano Gambella,Luca Barabino,Stefania Bregante,Carmen di Grazia,Alida Dominietto,Anna Ghiso,Andrea Guastalla,Luca Marri,Alberto Serio,Silvia Luchetti,Riccardo Varaldo,Antonella Laudisi,Giulia Francia,Monica Passannante,Federico Ivaldi,Alessandra Bo,Raffaele De Palma,Emanuele Angelucci
Cryopreservation of allogeneic peripheral blood stem cells was widely adopted during the SARS-CoV-2 pandemic. We evaluated transplant-related complications and graft product composition in a retrospective (n = 62) and prospective (n = 47) series of patients transplanted from an HLA-identical donor comparing cryopreserved (n = 50) versus fresh (n = 59) peripheral blood stem cell grafts. Primary endpoints were hematological reconstitution and cumulative incidence of grade II-IV acute graft versus host disease. Median times to neutrophil and platelet recovery were longer in the cryopreserved group compared with the fresh group: 18 vs. 16 days (p < 0.001) and 20 vs. 14 days (p < 0.001), respectively. The cumulative incidence of grade II-IV acute graft versus host disease at day 100 and of poor graft function at 1 year was significantly higher in the cryopreserved group: 34% vs. 10.1%, (p = 0.0017) and 20% vs. 1.6% (p < 0.001), respectively. To characterize immune cell profiles in fresh and cryopreserved samples, a representative subset was analyzed by mass cytometry, revealing a higher number of T-cell populations known to modulate immune responses and promote graft engraftment in fresh samples. Thus, cryopreservation of allogeneic peripheral blood stem cells is associated with increased incidence of acute graft versus host disease and poor graft function.
{"title":"Cryopreservation of Hemopoietic Cells for Allotransplant: Altered Immune Cell Subsets and Clinical Implications.","authors":"Anna Maria Raiola,Paola Contini,Massimiliano Gambella,Luca Barabino,Stefania Bregante,Carmen di Grazia,Alida Dominietto,Anna Ghiso,Andrea Guastalla,Luca Marri,Alberto Serio,Silvia Luchetti,Riccardo Varaldo,Antonella Laudisi,Giulia Francia,Monica Passannante,Federico Ivaldi,Alessandra Bo,Raffaele De Palma,Emanuele Angelucci","doi":"10.1002/ajh.70255","DOIUrl":"https://doi.org/10.1002/ajh.70255","url":null,"abstract":"Cryopreservation of allogeneic peripheral blood stem cells was widely adopted during the SARS-CoV-2 pandemic. We evaluated transplant-related complications and graft product composition in a retrospective (n = 62) and prospective (n = 47) series of patients transplanted from an HLA-identical donor comparing cryopreserved (n = 50) versus fresh (n = 59) peripheral blood stem cell grafts. Primary endpoints were hematological reconstitution and cumulative incidence of grade II-IV acute graft versus host disease. Median times to neutrophil and platelet recovery were longer in the cryopreserved group compared with the fresh group: 18 vs. 16 days (p < 0.001) and 20 vs. 14 days (p < 0.001), respectively. The cumulative incidence of grade II-IV acute graft versus host disease at day 100 and of poor graft function at 1 year was significantly higher in the cryopreserved group: 34% vs. 10.1%, (p = 0.0017) and 20% vs. 1.6% (p < 0.001), respectively. To characterize immune cell profiles in fresh and cryopreserved samples, a representative subset was analyzed by mass cytometry, revealing a higher number of T-cell populations known to modulate immune responses and promote graft engraftment in fresh samples. Thus, cryopreservation of allogeneic peripheral blood stem cells is associated with increased incidence of acute graft versus host disease and poor graft function.","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"42 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147350513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lukáš Homola,Piotr Korbal,Isaac Thomsen,Elizabeth Wang,Yanping Liu,Ashlesh Murthy,Robert O'Neill,Jason D Maguire,Beth Moughan,Paula Peyrani,Annaliesa S Anderson,Johannes Beeslaar
{"title":"A Phase 4 Trial to Describe the Immunogenicity, Safety, and Tolerability of MenB-fHbp in Participants > 10 Years of Age With Asplenia or Complement Deficiency.","authors":"Lukáš Homola,Piotr Korbal,Isaac Thomsen,Elizabeth Wang,Yanping Liu,Ashlesh Murthy,Robert O'Neill,Jason D Maguire,Beth Moughan,Paula Peyrani,Annaliesa S Anderson,Johannes Beeslaar","doi":"10.1002/ajh.70261","DOIUrl":"https://doi.org/10.1002/ajh.70261","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"65 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147329289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Using data from a nationwide Japanese registry, we evaluated the impact of the total body irradiation (TBI) dose in reduced-intensity conditioning (RIC) for allogeneic hematopoietic cell transplantation (allo-HCT) in patients with acute myeloid leukemia (AML). Adults undergoing their first allo-HCT with RIC between 2010 and 2021 were classified into three groups: non-TBI, low-TBI (2 to < 4 Gy), or moderate-TBI (4-8 Gy). Outcomes were analyzed separately for patients in complete remission (CR, n = 1949) and those in the non-CR group (n = 1484). Non-TBI was associated with higher overall mortality than low-TBI (hazard ratio [HR], 1.27; 95% confidence interval [CI], 1.03-1.56 in CR; HR, 1.19; 95% CI, 1.00-1.42 in non-CR). Moderate-TBI showed no significant difference in overall mortality compared to low-TBI (HR, 0.96; 95% CI, 0.80-1.15 in CR; HR, 0.89; 95% CI, 0.77-1.05 in non-CR). Among patients in the CR group with matched sibling donors, moderate-TBI reduced overall mortality (HR, 0.33; 95% CI, 0.17-0.64) and relapse (HR, 0.29; 95% CI, 0.12-0.69). In cord blood transplantation, non-TBI increased relapse in CR (HR, 2.73; 95% CI, 1.48-5.06) and overall mortality in non-CR (HR, 1.62; 95% CI, 1.19-2.19). In haploidentical transplants, non-TBI increased relapse (HR, 5.52; 95% CI, 1.72-17.72 in CR; HR, 1.54; 95% CI, 1.04-2.30 in non-CR). The incidence of secondary primary malignancies did not differ according to the use or dose of TBI. In conclusion, adding low- or moderate-TBI to RIC may improve disease control and survival without increasing non-relapse mortality.
{"title":"Impact of Total Body Irradiation Dose in Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia.","authors":"Shohei Mizuno,Akiyoshi Takami,Koji Kawamura,Kaito Harada,Masayoshi Masuko,Hideki Nakasone,Tomomi Toubai,Noriko Doki,Masatsugu Tanaka,Satoshi Yoshihara,Makoto Onizuka,Shigesaburo Miyakoshi,Yuta Katayama,Naoyuki Uchida,Takahiro Fukuda,Tetsuya Eto,Jun Ishikawa,Hirohisa Nakamae,Noboru Asada,Masashi Sawa,Yoshinobu Kanda,Yoshiko Atsuta,Takaaki Konuma,Masamitsu Yanada","doi":"10.1002/ajh.70265","DOIUrl":"https://doi.org/10.1002/ajh.70265","url":null,"abstract":"Using data from a nationwide Japanese registry, we evaluated the impact of the total body irradiation (TBI) dose in reduced-intensity conditioning (RIC) for allogeneic hematopoietic cell transplantation (allo-HCT) in patients with acute myeloid leukemia (AML). Adults undergoing their first allo-HCT with RIC between 2010 and 2021 were classified into three groups: non-TBI, low-TBI (2 to < 4 Gy), or moderate-TBI (4-8 Gy). Outcomes were analyzed separately for patients in complete remission (CR, n = 1949) and those in the non-CR group (n = 1484). Non-TBI was associated with higher overall mortality than low-TBI (hazard ratio [HR], 1.27; 95% confidence interval [CI], 1.03-1.56 in CR; HR, 1.19; 95% CI, 1.00-1.42 in non-CR). Moderate-TBI showed no significant difference in overall mortality compared to low-TBI (HR, 0.96; 95% CI, 0.80-1.15 in CR; HR, 0.89; 95% CI, 0.77-1.05 in non-CR). Among patients in the CR group with matched sibling donors, moderate-TBI reduced overall mortality (HR, 0.33; 95% CI, 0.17-0.64) and relapse (HR, 0.29; 95% CI, 0.12-0.69). In cord blood transplantation, non-TBI increased relapse in CR (HR, 2.73; 95% CI, 1.48-5.06) and overall mortality in non-CR (HR, 1.62; 95% CI, 1.19-2.19). In haploidentical transplants, non-TBI increased relapse (HR, 5.52; 95% CI, 1.72-17.72 in CR; HR, 1.54; 95% CI, 1.04-2.30 in non-CR). The incidence of secondary primary malignancies did not differ according to the use or dose of TBI. In conclusion, adding low- or moderate-TBI to RIC may improve disease control and survival without increasing non-relapse mortality.","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"248 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147329290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thomas C Fisher-Heath, Colin Rogerson, Benjamin Nti, Patrick T McGann, Matthew Hays, Seethal A Jacob
{"title":"Diagnosis and Management of Acute Chest Syndrome in Children With Sickle Cell Disease.","authors":"Thomas C Fisher-Heath, Colin Rogerson, Benjamin Nti, Patrick T McGann, Matthew Hays, Seethal A Jacob","doi":"10.1002/ajh.70260","DOIUrl":"https://doi.org/10.1002/ajh.70260","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147300873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sara El Aouhel, Vanessa Bellegarde, Stennio Da Silva Faria, Tristan St-Laurent, Estelle Lecluze, Anne-Laure Pham Hung d'Alexandry d'Orengiani, Frédéric Galactéros, Pablo Bartolucci, Marc-André Legault, Guillaume Lettre, Thomas Pincez
Acute chest syndrome (ACS) is a severe complication of sickle cell disease (SCD) occurring in ~50% of patients, some presenting frequent episodes. We lack tools to identify patients at high risk of ACS occurrence or frequent episodes. Epidemiological studies have found an association between asthma and ACS, but whether this link is causal is unclear. We used polygenic scores (PGS) to analyze whether the genetic propensity for asthma was associated with ACS and could be used to stratify the risk of ACS. We identified that PGS for asthma (PGSasthma) was associated with ACS rate (number of episodes per year), but not ACS occurrence, in both the CSSCD (n = 1278) and the GEN-MOD (n = 406) prospective SCD cohorts, independently of fetal hemoglobin (HbF) (β = 0.17, standard error = 0.06, p = 0.006). This effect was most pronounced in patients with low HbF levels. Combining PGSasthma and HbF identified a population at high risk of frequent ACS after a first episode: individuals within the highest PGSasthma quintile and the lowest HbF quintile. Finally, we found that the genetic correlation between these two conditions only partially overlapped. This suggests that genetically determined asthma is not the unique contributor to the genetic propensity for ACS and that other genetic determinants may also play a role. In sum, our results suggest that patients with a high genetic propensity for asthma are prone to frequent ACS if not protected by high HbF levels. Combining PGSasthma and HbF may allow identifying patients at high risk of frequent ACS after a first episode for personalized management.
{"title":"Genetic Contribution to Asthma Informs Acute Chest Syndrome Pathophysiology and Risk Stratification.","authors":"Sara El Aouhel, Vanessa Bellegarde, Stennio Da Silva Faria, Tristan St-Laurent, Estelle Lecluze, Anne-Laure Pham Hung d'Alexandry d'Orengiani, Frédéric Galactéros, Pablo Bartolucci, Marc-André Legault, Guillaume Lettre, Thomas Pincez","doi":"10.1002/ajh.70262","DOIUrl":"https://doi.org/10.1002/ajh.70262","url":null,"abstract":"<p><p>Acute chest syndrome (ACS) is a severe complication of sickle cell disease (SCD) occurring in ~50% of patients, some presenting frequent episodes. We lack tools to identify patients at high risk of ACS occurrence or frequent episodes. Epidemiological studies have found an association between asthma and ACS, but whether this link is causal is unclear. We used polygenic scores (PGS) to analyze whether the genetic propensity for asthma was associated with ACS and could be used to stratify the risk of ACS. We identified that PGS for asthma (PGS<sub>asthma</sub>) was associated with ACS rate (number of episodes per year), but not ACS occurrence, in both the CSSCD (n = 1278) and the GEN-MOD (n = 406) prospective SCD cohorts, independently of fetal hemoglobin (HbF) (β = 0.17, standard error = 0.06, p = 0.006). This effect was most pronounced in patients with low HbF levels. Combining PGS<sub>asthma</sub> and HbF identified a population at high risk of frequent ACS after a first episode: individuals within the highest PGS<sub>asthma</sub> quintile and the lowest HbF quintile. Finally, we found that the genetic correlation between these two conditions only partially overlapped. This suggests that genetically determined asthma is not the unique contributor to the genetic propensity for ACS and that other genetic determinants may also play a role. In sum, our results suggest that patients with a high genetic propensity for asthma are prone to frequent ACS if not protected by high HbF levels. Combining PGS<sub>asthma</sub> and HbF may allow identifying patients at high risk of frequent ACS after a first episode for personalized management.</p>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147300846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ibrahim Gwarzo, Harish Chandra Dega, David C Brousseau
{"title":"Minutes Matter: An Audit of the Timeliness of Opioid Administration for Sickle Cell Disease Pain in the Emergency Department and Association With Disposition.","authors":"Ibrahim Gwarzo, Harish Chandra Dega, David C Brousseau","doi":"10.1002/ajh.70253","DOIUrl":"https://doi.org/10.1002/ajh.70253","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147289145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Olivier Pouliot, Costa Kazadi, Chrystelle Charles, Jonathan St-Onge, Olena Bereznyakova, Marie-Andrée Panzini, Julian Rivillas, Christian Stapf, Gregory Jacquin, Stéphanie Forté
{"title":"Feasibility and Characteristics of Systematic Transcranial Doppler in Adults With Sickle Cell Disease: A Cross-Sectional Single Center Study.","authors":"Olivier Pouliot, Costa Kazadi, Chrystelle Charles, Jonathan St-Onge, Olena Bereznyakova, Marie-Andrée Panzini, Julian Rivillas, Christian Stapf, Gregory Jacquin, Stéphanie Forté","doi":"10.1002/ajh.70252","DOIUrl":"https://doi.org/10.1002/ajh.70252","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147281912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：